Brought to you by 
Kissei pays $33mm up front for rights to Rigel's Tavalisse
30 Oct 2018
Executive Summary
Rigel Pharmaceuticals Inc. licensed Kissei Pharmaceutical Co. Ltd. exclusive rights to develop and sell its thrombocytopenia drug Tavalisse (fostamatinib disodium hexadydrate) in Japan, China, Taiwan, and the Republic of Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kissei pays $33mm up front for rights to Rigel's Tavalisse
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice